Home > Molecular Glues

Molecular Glues

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC49931 NVP-DKY709 Featured NVP-DKY709 is a powerful IKZF2 inhibitor with significant potential for cancer therapy.
DC50173 dCeMM4 Featured dCeMM4 (Compound 5) is a molecular glue degrader that facilitates the ubiquitination and degradation of cyclin K. It achieves this by promoting an interaction between the CDK12-cyclin K complex and the CRL4B ligase complex.
DC50183 dCeMM2 Featured dCeMM2 (Compound 2) is a molecular glue degrader that drives the ubiquitination and degradation of cyclin K. It achieves this by facilitating an interaction between the CDK12-cyclin K complex and the CRL4B ligase complex.
DC50184 dCeMM3 Featured dCeMM3 (Compound 3) is a molecular glue degrader that facilitates the ubiquitination and degradation of cyclin K. It achieves this by promoting an interaction between the CDK12-cyclin K complex and the CRL4B ligase complex.
DC50245 CFT7455 Featured CFT7455 is an orally bioavailable degrader of the zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). It functions as an anticancer agent by binding with high affinity to the cereblon E3 ligase, exhibiting a Kd of 0.9 nM (WO2022032132A1; Compound 1).
DC70109 (R)-CR8 Featured (R)-CR8 (CR8), a second-generation derivative of Roscovitine, is a highly effective inhibitor of CDK1/2/5/7/9. It exhibits inhibitory activity against CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM), and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and demonstrates neuroprotective properties. Additionally, it functions as a molecular glue degrader, specifically targeting and depleting cyclin K.
DC70900 WBC100 Featured WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active molecular glue degrader targeting c-Myc. It facilitates the degradation of c-Myc through the ubiquitin E3 ligase CHIP-mediated 26S proteasome pathway. WBC100 is specifically utilized for research involving c-Myc overexpressing tumors.
DC70978 Thalidomide-piperazine hydrochloride Featured Thalidomide-piperazine hydrochloride represents a chemically modified derivative of the prototypic immunomodulatory drug, featuring a piperazine moiety that enhances solubility while preserving the compound's unique biological properties.
DC71590 (Rac)-CFT7455 Featured (Rac)-CFT7455 is a potent, racemic small-molecule degrader of the zinc finger transcription factors ​IKZF1 (Ikaros) and IKZF3 (Aiolos), operating through ​ubiquitin-proteasome-mediated degradation. It demonstrates exceptional cellular potency, with a ​GI50 of 0.05 nM in NCI-H929.1 cells. As the racemic form of ​CFT7455, it retains the same ​anticancer activity by selectively targeting IKZF1/3 for proteasomal destruction.
DC60254 HQ461 Featured HQ461 is a molecular glue degrader that facilitates the interaction between CDK12 and the DDB1-CUL4-RBX1 E3 ubiquitin ligase, resulting in the polyubiquitination and subsequent degradation of the CDK12-interacting protein Cyclin K (CCNK). This degradation impairs CDK12 function, leading to reduced phosphorylation of its substrates, downregulation of DNA damage response genes, and ultimately, cell death.
DC71971 SJPYT-195 Featured SJPYT-195 is a potent cytotoxic degrader of GSPT1, serving as a valuable compound for PROTAC (proteolysis-targeting chimera) synthesis and targeted protein degradation research.
DC72103 Golcadomide（CC-99282） Featured Golcadomide (CC-99282) is a highly potent and orally bioavailable CRBN E3 ligase modulator (CELMoD). It interacts with the CRL4 CRBN E3 ubiquitin ligase substrate receptor CRBN, facilitating the recruitment and ubiquitin-mediated proteasomal degradation of the transcription factors Ikaros and Aiolos. Golcadomide holds significant promise for research in cancer-related areas, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
DC60460 SJ3149 Featured SJ3149 is a highly selective and potent molecular glue degrader targeting CK1α protein, exhibiting broad antiproliferative activity. It is a valuable tool for cancer research.
DC60777 EN450 Featured EN450 is a cysteine-reactive covalent molecular glue degrader specifically designed to target NF-κB.
DC60500 NVS-STG2 Featured NVS-STG2 is a molecular glue that targets STING and activates STING-mediated immune signaling. It promotes higher-order oligomerization of human STING by binding to pockets between adjacent STING dimer transmembrane domains, effectively functioning as a molecular glue. NVS-STG2 enhances the activity of cGAMP by inducing the formation of more abundant and larger oligomers. It demonstrates significant antitumor activity in animal models.
DCC3332 Mg-277 Featured MG-277, a molecular glue degrader, efficiently induces the degradation of the translation termination factor GSPT1, based on the Cereblon E3 ligand, with a DC50 of 1.3 nM. It potently inhibits tumor cell growth in a p53-independent manner, demonstrating IC50 values of 3.5 nM for RS4;11 cells and 3.4 nM for p53 mutant RS4;11/IRMI-2 cells. MG-277 exhibits significant anticancer activity.
DCC5425 Voclosporin Featured Voclosporin (ISAtx-247) is an inhibitor of calcineurin (PP2B), also known as CN, exhibiting its activity through targeted suppression of this enzyme.
DCC5670 Zxh-1-161 Featured ZXH-1-161 is a potent cereblon (CRBN) modulator, demonstrating an IC50 value of 39 nM in MM1.S wild-type cells. It exhibits selective degradation activity toward GSPT1 and is a valuable tool for researching multiple myeloma.
DC65810 KT-333 Featured KT-333 is a first-in-class molecular glue that induces ​selective degradation of STAT3 via the ubiquitin-proteasome system by simultaneously engaging ​STAT3 and the VHL E3 ligase. This novel mechanism enables potent ​STAT3 depletion with minimal off-target effects, demonstrating strong ​anti-tumor activity in hematologic malignancies.
DC60549 IBG3 Featured IBG3 is a PROTAC-like degrader that exhibits superior degradation efficiency for BRD4 and BRD2 compared to IBG1, with DC50 values of 6.7 pM and 8.6 pM, respectively.
DC60559 PT-179 Featured PT-179 is a novel orthogonal immunomodulatory drug (IMiD) derivative that selectively binds to CRBN without inducing degradation of off-target proteins. It demonstrates potent activity in degrading proteins fused to SD40, regardless of whether the fusion occurs at the N or C terminus.
DC73095 CCT373566 Featured CCT373566 is a highly potent, in vivo active BCL6 degrader, demonstrating an IC50 of 2.2 nM in TR-FRET assays and a DC50 of 0.7 nM in cellular BCL6 degradation assays.
DC73176 NCT02 Featured NCT02 is a small molecule that triggers the ubiquitination of cyclin K (CCNK), leading to its proteasomal degradation along with its complex partner CDK12.
DC74482 CC-3240 Featured CC-3240 is an optimized molecular glue degrader derived from ​CC-8977, demonstrating high-affinity binding to ​CaMKK2 (IC50 = 9 nM) and potent degradation efficacy (DC50 = 100 nM in THP1 cells, Dmax = 92%). This novel compound effectively hijacks the ubiquitin-proteasome system to induce ​targeted CaMKK2 depletion, offering a superior pharmacological approach over traditional kinase inhibition.
DC74572 DEG-77 Featured DEG-77 is a cereblon-dependent degrader targeting IKZF2 and casein kinase 1α (CK1α). It effectively blocks cell growth and delays leukemia progression in both murine and human acute myeloid leukemia (AML) mouse models.
DC60567 dCeMM1 Featured dCeMM1 is a molecular glue degrader targeting RBM39. It functions by redirecting the activity of the CRL4DCAF15 ligase, leading to a reduction in RBM39 levels in WT KBM7 cells.
DC60572 NST-628 Featured NST-628 is a brain-penetrant molecular glue targeting the MAPK pathway, effectively inhibiting RAF phosphorylation and MEK activation. By binding to RAF, it disrupts the formation of BRAF-CRAF and BRAF-ARAF heterodimers, thereby blocking the RAS-MAPK signaling cascade. NST-628 exhibits potent anti-tumor activity in RAS- and RAF-driven cancers, demonstrating significant efficacy in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumor models.
DC60617 dWIZ-1 Featured dWIZ-1 is a first-in-class molecular glue degrader that specifically targets the WIZ transcription factor for proteasomal degradation, leading to potent induction of fetal hemoglobin (HbF) in erythroblasts. This novel compound functions by enhancing the interaction between CRBN and WIZ, demonstrating an EC50 of 547 nM for CRBN-WIZ complex formation.
DC60624 OPB-171775 Featured OPB-171775 represents a breakthrough in GIST treatment as a first-in-class, non-tyrosine kinase inhibitor (non-TKI) compound that demonstrates potent antitumor activity independent of KIT mutation status. Unlike conventional TKIs that target oncogenic kinases, OPB-171775 operates through an innovative mechanism by orchestrating a protein-protein interaction between phosphodiesterase 3A (PDE3A) and Schlafen 12 (SLFN12).
DC60634 LL-K12-18 Featured LL-K12-18 is a highly potent dual-site molecular glue that induces the formation of the CDK12-DDB1 complex, exhibiting an ​EC50 of 0.37 nM. It demonstrates ​80-fold greater potency than SR-4835 in ​MDA-MB-231 cells and a remarkable ​307-fold increase in potency (EC50 = 0.03 nM) in ​MDA-MB-468 cells, while its ​degradation efficiency (DC50 = 0.38 nM) is ​50-fold enhanced.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia